Hormone Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Hormone Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-10-29Clinical Trial Update: A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer [Phase 3]
Phase 3 clinical trial evaluating elinzanetant versus placebo for vasomotor symptoms caused by adjuvant endocrine therapy in women with, or …
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) [Phase 2]
Phase 2 clinical trial update evaluating preoperative pembrolizumab plus radiation therapy in breast cancer, including triple-negative and H…
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy [Phase 3]
A Phase 3 clinical trial comparing sacituzumab govitecan with physician's choice in HR+/HER2- metastatic breast cancer after endocrine thera…
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating adaptive therapy with capecitabine for metastatic estrogen receptor-positive, HER2-negative breast ca…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of combining camizestrant with ribociclib in hormone receptor-positive breast canc…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
Clinical trial update on Invikafusp alfa in combination with sacituzumab govitecan in adults with advanced solid tumors, including triple-ne…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. [Phase 2]
A Phase 2 clinical trial evaluating abemaciclib in combination with endocrine therapy for older patients with breast cancer is currently rec…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: Development of a New Remote Monitoring Model for Patients With HR+HER2- Breast Cancer in Treatment With CDK4/6 Inhibitors and Hormone Therapy
A clinical trial update describes the development of a remote monitoring model for patients with HR-positive, HER2-negative breast cancer tr…
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC
This completed clinical trial update analyzes treatment patterns and clinical outcomes of palbociclib combinations in hormone receptor-posit…
-
FDA approval · 2025-09-17FDA Approved: FULVESTRANT — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Fulvestrant filed by Hikma Pharmaceuticals USA Inc. This action formalizes an updated regula…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers [Phase 2]
A Phase 2 clinical trial update for SC-101 in nectin-4 amplified cancers, including triple-negative breast cancer and hormone receptor-posit…
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer [Phase 1, Phase 2]
This update covers a dose-escalation/expansion study of OP-1250 in advanced HR+, HER2- breast cancer, which completed Phase 1 and Phase 2. N…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: Comparison of the Breast Tumor Microenvironment
This document provides an update on a clinical trial studying the breast tumor microenvironment in breast cancer subtypes, including triple-…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy [Phase 2]
Phase 2 neoadjuvant breast cancer trial at Fudan University Shanghai Cancer Center evaluating a precision-platform therapy; the study is cur…
-
CLINICAL_TRIALS trial_result · 2025-08-21Clinical Trial Update: Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer [Phase 2]
This is a Phase 2 clinical trial update evaluating adebrelimab in combination with dalpiciclib and standard endocrine therapy for HR+/HER2- …
-
CLINICAL_TRIALS research · 2025-08-20Clinical Trial Update: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib [Phase 2]
This Phase 2 trial update describes using circulating tumor DNA in the blood to guide which patients with HR-positive, HER2-negative metasta…
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03) [Phase 2]
A Phase 2 neoadjuvant trial is evaluating chemotherapy in combination with anlotinib and Benmelstobart for HR+/HER2- breast cancer; the stud…
-
CLINICAL_TRIALS trial_result · 2025-08-12Clinical Trial Update: Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01) [Phase 2]
Phase 2 neoadjuvant trial evaluating chemotherapy in combination with toripalimab for hormone receptor-positive, HER2-negative breast cancer…
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer
Clinical trial update describes establishing molecular profiling to guide individual treatment decisions in early breast cancer. The study i…
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer [NA]
This clinical trial update describes a study to assess whether prolonged overnight fasting and/or exercise affects fatigue and other patient…
-
CLINICAL_TRIALS other · 2025-08-01Clinical Trial Update: Neoadjuvant Breast Cancer Time Restricted Eating [NA]
This ClinicalTrials.gov entry updates a neoadjuvant breast cancer study investigating time-restricted eating. The study is currently recruit…
-
CLINICAL_TRIALS trial_result · 2025-07-25Clinical Trial Update: Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
A retrospective analysis examines second-line therapies used after progression on a CDK4/6 inhibitor plus hormonal therapy in patients with …
-
CLINICAL_TRIALS trial_result · 2025-07-25Clinical Trial Update: A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer
This is a completed real-world study of ribociclib used as first-line therapy for metastatic hormone receptor-positive, HER2-negative breast…
-
CLINICAL_TRIALS research · 2025-07-22Clinical Trial Update: Fasting-Mimicking Diet as an Adjunct to Neoadjuvant Chemotherapy for Hormone-Receptor-Positive Breast Cancer [NA]
A clinical trial update evaluating whether a fasting-mimicking diet can augment neoadjuvant chemotherapy for hormone-receptor-positive breas…
-
CLINICAL_TRIALS trial_result · 2025-07-20Clinical Trial Update: Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer [Phase 2]
Phase 2 trial evaluating the impact of combining endocrine therapy with abemaciclib on host and tumor immune cell repertoire in advanced ER+…